Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-1.46%)
USD 1.35
(-1.46%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 482.43 Thousand USD | 418.54% |
| 2022 | 93.03 Thousand USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | -100.0% |
| 2019 | 31.56 Thousand USD | -97.39% |
| 2018 | 1.2 Million USD | 426.38% |
| 2017 | -369.99 Thousand USD | -270.52% |
| 2016 | 216.97 Thousand USD | -93.88% |
| 2015 | 3.54 Million USD | 257.54% |
| 2014 | 991.19 Thousand USD | -68.21% |
| 2013 | 3.11 Million USD | -53.11% |
| 2012 | 6.64 Million USD | 47.11% |
| 2011 | 4.52 Million USD | 96.7% |
| 2010 | 2.29 Million USD | 42.97% |
| 2009 | 1.6 Million USD | 7.9% |
| 2008 | 1.48 Million USD | 36.3% |
| 2007 | 1.09 Million USD | 17.08% |
| 2006 | 933.57 Thousand USD | 47.46% |
| 2005 | 633.1 Thousand USD | 45.96% |
| 2004 | 433.76 Thousand USD | 32.05% |
| 2003 | 328.49 Thousand USD | -2.93% |
| 2002 | 338.4 Thousand USD | 692.75% |
| 2001 | 42.68 Thousand USD | -83.38% |
| 2000 | 256.86 Thousand USD | 1587.36% |
| 1999 | -17.27 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 183.98 Thousand USD | 18.21% |
| 2024 Q2 | 299.43 Thousand USD | 62.75% |
| 2023 FY | 482.43 Thousand USD | 418.54% |
| 2023 Q2 | 97.68 Thousand USD | 92.74% |
| 2023 Q1 | 50.68 Thousand USD | -17.3% |
| 2023 Q3 | 178.42 Thousand USD | 82.66% |
| 2023 Q4 | 155.64 Thousand USD | -12.77% |
| 2022 Q1 | - USD | 0.0% |
| 2022 FY | 93.03 Thousand USD | 0.0% |
| 2022 Q4 | 61.28 Thousand USD | 92.98% |
| 2022 Q3 | 31.75 Thousand USD | 2441.81% |
| 2022 Q2 | -1356.00 USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | -100.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 FY | 31.56 Thousand USD | -97.39% |
| 2019 Q2 | 10.53 Thousand USD | 0.05% |
| 2019 Q3 | 23.17 Thousand USD | 119.97% |
| 2019 Q4 | -12.67 Thousand USD | -154.7% |
| 2019 Q1 | 10.53 Thousand USD | -98.65% |
| 2018 Q4 | 781.15 Thousand USD | 262.61% |
| 2018 FY | 1.2 Million USD | 426.38% |
| 2018 Q1 | 110.93 Thousand USD | 235.15% |
| 2018 Q3 | 215.42 Thousand USD | 115.24% |
| 2018 Q2 | 100.08 Thousand USD | -9.78% |
| 2017 Q3 | -101.79 Thousand USD | -14.67% |
| 2017 FY | -369.99 Thousand USD | -270.52% |
| 2017 Q1 | -97.34 Thousand USD | 15.22% |
| 2017 Q2 | -88.77 Thousand USD | 8.81% |
| 2017 Q4 | -82.08 Thousand USD | 19.36% |
| 2016 Q3 | -100.83 Thousand USD | -153.5% |
| 2016 Q1 | 619.17 Thousand USD | 37.74% |
| 2016 Q2 | 188.45 Thousand USD | -69.56% |
| 2016 FY | 216.97 Thousand USD | -93.88% |
| 2016 Q4 | -114.81 Thousand USD | -13.87% |
| 2015 FY | 3.54 Million USD | 257.54% |
| 2015 Q4 | 449.51 Thousand USD | -21.02% |
| 2015 Q3 | 569.13 Thousand USD | 10.85% |
| 2015 Q2 | 513.43 Thousand USD | -74.48% |
| 2015 Q1 | 2.01 Million USD | 1170.05% |
| 2014 Q2 | 428.61 Thousand USD | 9.1% |
| 2014 Q3 | 357.72 Thousand USD | -16.54% |
| 2014 Q4 | -188 Thousand USD | -152.56% |
| 2014 FY | 991.19 Thousand USD | -68.21% |
| 2014 Q1 | 392.86 Thousand USD | -20.12% |
| 2013 Q2 | 1.06 Million USD | 1.95% |
| 2013 Q4 | 491.8 Thousand USD | -4.75% |
| 2013 FY | 3.11 Million USD | -53.11% |
| 2013 Q1 | 1.04 Million USD | 2.98% |
| 2013 Q3 | 516.32 Thousand USD | -51.53% |
| 2012 FY | 6.64 Million USD | 47.11% |
| 2012 Q3 | 761.37 Thousand USD | -71.86% |
| 2012 Q2 | 2.7 Million USD | 24.77% |
| 2012 Q1 | 2.16 Million USD | -2.74% |
| 2012 Q4 | 1.01 Million USD | 33.27% |
| 2011 FY | 4.52 Million USD | 96.7% |
| 2011 Q2 | 755.06 Thousand USD | 4.84% |
| 2011 Q3 | 815.54 Thousand USD | 8.01% |
| 2011 Q4 | 2.22 Million USD | 173.36% |
| 2011 Q1 | 720.22 Thousand USD | 0.04% |
| 2010 FY | 2.29 Million USD | 42.97% |
| 2010 Q4 | 719.96 Thousand USD | -5.64% |
| 2010 Q3 | 762.99 Thousand USD | 65.17% |
| 2010 Q1 | 4291.00 USD | -98.64% |
| 2010 Q2 | 461.94 Thousand USD | 10665.35% |
| 2009 Q1 | 406.15 Thousand USD | 10.15% |
| 2009 Q2 | 451.33 Thousand USD | 11.12% |
| 2009 Q4 | 315.1 Thousand USD | -27.53% |
| 2009 Q3 | 434.79 Thousand USD | -3.66% |
| 2009 FY | 1.6 Million USD | 7.9% |
| 2008 Q3 | 390.44 Thousand USD | 21.52% |
| 2008 Q2 | 321.31 Thousand USD | -21.48% |
| 2008 Q1 | 409.23 Thousand USD | 29.8% |
| 2008 FY | 1.48 Million USD | 36.3% |
| 2008 Q4 | 368.72 Thousand USD | -5.56% |
| 2007 Q4 | 315.28 Thousand USD | -0.18% |
| 2007 FY | 1.09 Million USD | 17.08% |
| 2007 Q1 | 217.06 Thousand USD | 25.63% |
| 2007 Q3 | 315.85 Thousand USD | 29.04% |
| 2007 Q2 | 244.78 Thousand USD | 12.77% |
| 2006 Q1 | 221.97 Thousand USD | 35.23% |
| 2006 Q3 | 350.77 Thousand USD | 86.54% |
| 2006 Q4 | 172.78 Thousand USD | -50.74% |
| 2006 FY | 933.57 Thousand USD | 47.46% |
| 2006 Q2 | 188.03 Thousand USD | -15.29% |
| 2005 FY | 633.1 Thousand USD | 45.96% |
| 2005 Q1 | 116.73 Thousand USD | -10.06% |
| 2005 Q4 | 164.14 Thousand USD | -34.63% |
| 2005 Q3 | 251.1 Thousand USD | 148.31% |
| 2005 Q2 | 101.12 Thousand USD | -13.37% |
| 2004 Q1 | 100.7 Thousand USD | -12.69% |
| 2004 Q4 | 129.78 Thousand USD | 48.69% |
| 2004 Q3 | 87.28 Thousand USD | -24.75% |
| 2004 Q2 | 115.98 Thousand USD | 15.17% |
| 2004 FY | 433.76 Thousand USD | 32.05% |
| 2003 Q4 | 115.34 Thousand USD | 23.41% |
| 2003 FY | 328.49 Thousand USD | -2.93% |
| 2003 Q3 | 93.46 Thousand USD | 39.14% |
| 2003 Q2 | 67.17 Thousand USD | 27.92% |
| 2003 Q1 | 52.51 Thousand USD | -45.41% |
| 2002 FY | 338.4 Thousand USD | 692.75% |
| 2002 Q3 | 140.77 Thousand USD | 89.79% |
| 2002 Q4 | 96.19 Thousand USD | -31.67% |
| 2002 Q2 | 74.17 Thousand USD | 172.21% |
| 2002 Q1 | 27.25 Thousand USD | 228.98% |
| 2001 Q2 | 24.11 Thousand USD | -58.17% |
| 2001 Q4 | -21.12 Thousand USD | -172.44% |
| 2001 Q3 | 29.16 Thousand USD | 20.96% |
| 2001 Q1 | 57.64 Thousand USD | -19.3% |
| 2001 FY | 42.68 Thousand USD | -83.38% |
| 2000 Q3 | 57.42 Thousand USD | -41.84% |
| 2000 Q2 | 98.74 Thousand USD | 237.37% |
| 2000 Q1 | 29.26 Thousand USD | 0.0% |
| 2000 Q4 | 71.43 Thousand USD | 24.4% |
| 2000 FY | 256.86 Thousand USD | 1587.36% |
| 1999 FY | -17.27 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 19879.951% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 95.879% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 250.993% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.595% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.87% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 1099.675% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 488.273% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 96.784% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -15452.321% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 95.074% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -633.984% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1512.688% |
| Mesoblast Limited | -35.16 Million USD | 101.372% |
| Marizyme, Inc. | 457.7 Thousand USD | -5.403% |
| Genus plc | 178.7 Million USD | 99.73% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.781% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -675.292% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -17.619% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 4485.755% |
| ContraFect Corporation | -154 Thousand USD | 413.268% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 1064.866% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -528.487% |
| IMV Inc. | -962.29 Thousand USD | 150.133% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 224.499% |
| MultiCell Technologies, Inc. | 49.32 USD | -978069.1% |
| ONE Bio Corp. | 20.12 Million USD | 97.603% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 98.802% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -886.571% |
| Q BioMed Inc. | -8988.00 USD | 5467.523% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.293% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 3227.807% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 98.912% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 142.26% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -589.19% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 9842.185% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -243.369% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 594.727% |
| GB Sciences, Inc. | -624.00 USD | 77412.981% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 660.786% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.994% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 232038.942% |
| Enzolytics Inc. | 30.7 Thousand USD | -1471.034% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.956% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 193.766% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 21.859% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.882% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 5547.527% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 675.359% |
| Kadimastem Ltd | -630.13 Thousand USD | 176.56% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 51.17% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 94.98% |
| BioStem Technologies, Inc. | 15.42 Million USD | 96.872% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 4176.324% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -173.24% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -173.24% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 64.452% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1763.562% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -7.197% |
| SYBLEU INC | 11.69 Thousand USD | -4024.769% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 89.531% |
| Bioxytran, Inc. | -8285.00 USD | 5922.969% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 229.339% |
| Neutra Corp. | 14.33 Thousand USD | -3265.42% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 688.333% |
| PureTech Health plc | -1.6 Million USD | 130.096% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 148.184% |
| IXICO plc | 3.27 Million USD | 85.247% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 169.515% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 126.937% |
| CSL Limited | 7.7 Billion USD | 99.994% |
| Cellectis S.A. | 18 Thousand USD | -2580.183% |